Replies to post #121627 on Biotech Values

[genisi]

I think we agree on Denosumab. It is a bone targeted drug that reduces skeletal-related events, so it can be categorized as an "anti bone metastases" drug or "anti bone disease" drug but it also has a disease-modifying activity in cancer, which qualifies it as an anti cancer drug, IMO.
Something I disagree with is the point that "secondary endpoints do not change the prospects for Xgeva to a material degree" (#msg-63233655). I think pain reduction is a material one, clinically and commercially.